Osaic Holdings’s Innate Pharma IPHA Stock Holding History

Osaic Holdings’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$3K	–	7473
2022 Q1	$3K	Hold	1,000	–	–	﹤0.01%	6736
2021 Q4	$5K	Sell	1,000 -1,000	-50%	-$5.32K	﹤0.01%	6630
2021 Q3	$12K	Buy	2,000 +1,000	+100%	+$4.31K	﹤0.01%	6090
2021 Q2	$3K	Sell	1,000 -1,000	-50%	-$3.99K	﹤0.01%	6592
2021 Q1	$9K	Buy	+2,000	New	+$8.93K	﹤0.01%	5930
2020 Q4	–	Sell	-2,000	Closed	-$8K	–	6483
2020 Q3	$8K	Hold	2,000	–	–	﹤0.01%	5382
2020 Q2	$14K	Hold	2,000	–	–	﹤0.01%	5003
2020 Q1	$13K	Buy	+2,000	New	+$13.5K	﹤0.01%	4866

Other funds holding IPHA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Osaic Holdings's IPHA Position: Q2 2022 in Review

Osaic Holdings sold out of Innate Pharma (IPHA) in Q2 2022, closing a stake of 1,000 shares — an estimated $3K sold.

Osaic Holdings first reported a position in IPHA in Q1 2020 and held it in 8 quarters. The position peaked at $14K in Q2 2020. 13 funds tracked by Wall St. Rank hold IPHA as of Q2 2022.

Osaic Holdings reported no remaining Innate Pharma position as of Q2 2022 after selling out during the quarter.
Osaic Holdings sold 1,000 Innate Pharma shares in Q2 2022, an estimated $3K.
Osaic Holdings first reported a position in Innate Pharma in Q1 2020 and held it in 8 quarters.
Osaic Holdings's Innate Pharma position peaked at $14K in Q2 2020.
13 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2022.

Based on Osaic Holdings's 13F filing for Q2 2022, filed 10 Aug 2022.